Two injections, two different jobs

Most patients arrive at this comparison expecting a ranking — PRP versus ChondroFiller injection, better or worse. The MRI report sitting in front of a consultant is what actually settles the question.

These two treatments are not interchangeable alternatives. The ChondroFiller injection is a structural collagen scaffold: injected under ultrasound guidance as an outpatient procedure, it forms a porous three-dimensional lattice inside a focal, well-defined cartilage defect, providing a framework that the patient's own cells can colonise. It is suited to discrete, MRI-confirmed lesions in an otherwise mechanically sound joint — typically in younger, active patients where healthy surrounding tissue and stable joint mechanics allow the scaffold to do its job. PRP (platelet-rich plasma) operates on an entirely different principle. It concentrates growth factors from the patient's own blood and acts on the joint's biological environment, reducing pro-inflammatory cytokines and stimulating repair across a wider area. That makes it the more appropriate choice when the clinical picture is one of diffuse osteoarthritic change or early-stage widespread chondropathy rather than a single defined structural lesion.

The question that matters, then, is not 'which injection is better' but 'which one matches what the scan shows.' No direct head-to-head randomised trial has compared the two treatments, so framing them as a ranked competition has no evidence behind it. Both are outpatient injectables, and neither is appropriate where disease has progressed to end-stage, bone-on-bone arthritis.

How the ChondroFiller injection works

The product itself is a liquid formulation of Type I collagen — the same structural protein found in native cartilage — manufactured by Meidrix Biomedicals GmbH in Germany and imported into the UK under individual patient prescription. At the London Cartilage Clinic on Harley Street, it is placed via an ultrasound-guided outpatient injection; no theatre, no general anaesthetic, no surgical incision.

What happens inside the joint is where the mechanism becomes distinctive. On contact with the neutral pH of the synovial space, the liquid collagen self-polymerises within approximately 3–5 minutes, forming a porous three-dimensional lattice that fills and stabilises the defect. The scaffold is entirely passive — it contains no donor cells and requires no laboratory preparation — but its architecture is designed to attract the patient's own chondrocyte progenitor cells. Over roughly 6–12 months, those cells migrate into the lattice and begin producing new cartilage matrix, a process called matrix-induced chondrogenesis. As the repair tissue forms, the collagen scaffold gradually resorbs over 1–2 years, leaving the patient's own regenerated tissue in its place.

ChondroFiller injection is CE-marked as a Class III medical device. It is designed for focal defects up to 3 cm² — extendable to 6 cm² where anatomy permits — in joints that are mechanically sound, and has been used across the knee, hip, ankle, shoulder, elbow, wrist, small hand joints, and the temporomandibular joint (TMJ). The key constraint is joint health: the surrounding cartilage and mechanics must be intact enough to allow the scaffold to do its job.

How PRP works and where it fits

PRP starts with a straightforward clinical preparation: a small volume of the patient's own blood is drawn, centrifuged to separate and concentrate the platelet fraction, and injected intra-articularly — typically within a single appointment. The concentrated platelets deliver a high dose of growth factors directly into the joint, working across several biological pathways simultaneously: moderating pro-inflammatory cytokines, supporting angiogenesis, offering a degree of cartilage protection, and stimulating chondrocyte proliferation and differentiation.

That multi-pathway action is what makes PRP well matched to a different clinical picture from the ChondroFiller injection. Where a scan shows diffuse degenerative change — early-to-mid osteoarthritis, generalised chondropathy, or cartilage thinning across multiple joint surfaces rather than failing at one defined point — modifying the inflammatory environment can meaningfully reduce pain and slow deterioration. A focal structural void, by contrast, is a physical problem that a biological modifier alone cannot fill.

A 2022 narrative review published in PMC, drawing on 13 clinical trials, confirmed PRP's positive effects on cartilage injury and joint function improvement. At twelve months, separate evidence places PRP above corticosteroid injection for symptomatic knee osteoarthritis across pain, stiffness, and exercise participation. The standing limitation is consistency: preparation methods, platelet concentrations, and dosing protocols vary considerably across studies, which means trial results are difficult to compare directly and no universal standard protocol currently exists.

Which treatment matches your cartilage damage

An MRI report landing in the patient's inbox is often the starting point for this decision — but interpreting what it means for treatment eligibility is a clinical task, not something symptoms alone can answer.

The clearest decision signal is lesion morphology. A discrete, MRI-confirmed focal cartilage defect — typically ICRS Grade III or IV, measuring up to 3 cm² (extendable to 6 cm² in selected cases) — in an otherwise mechanically sound joint is the territory the ChondroFiller injection is designed for. Patients in this group tend to be younger or physically active, with healthy surrounding tissue, no significant joint instability, and intact mechanics. PRP maps to a different MRI picture: diffuse degenerative change, early-to-mid osteoarthritis, or generalised chondropathy where no single repairable structural void is visible. The aim there is biological — modifying the joint environment rather than scaffolding a specific defect site. Both treatments fall outside their range where imaging shows end-stage, bone-on-bone loss.

What the MRI shows — not symptom severity, how long pain has been present, or what a patient considers affordable — is the primary eligibility filter. Two patients with near-identical pain levels can have entirely different scan findings and follow entirely different pathways as a result.

A specialist assessment at the London Cartilage Clinic on Harley Street is the necessary next step for anyone in this position. No patient should self-select between these options on the basis of symptoms alone, and no comparison of costs or reviews replaces a clinical read of the actual imaging.

What the evidence shows for each

The ChondroFiller injection has roughly twenty years of clinical history across Europe, yet its evidence base is thinner than that longevity might suggest. Clinical data report approximately 70–85% symptom-relief success rates in focal defect studies; around 80% of patients in published series rated their outcomes as good or very good and said they would choose the treatment again. In knee studies, improvements in the IKDC functional score in the region of 30 points have been reported — a meaningful functional gain by any clinical measure. What those figures do not yet have behind them is a body of large-scale, high-quality randomised controlled trials; ChondroFiller is also not FDA-approved. That evidence gap matters when patients are weighing clinical experience against controlled data, and it should be part of any honest informed-consent conversation.

For PRP, the relevant synthesis at this stage is one of timing rather than repetition of the mechanistic evidence set out in the previous section. The functional improvements documented across clinical trials follow a similar arc to ChondroFiller's: gains are not immediate, with published studies placing meaningful benefit at six to twelve months post-injection. That parallel matters for expectation-setting — both injections require patience over the same window before a fair clinical assessment is possible.

What that convergence does not imply is equivalence. The mechanism and the clinical target remain fundamentally different, and the diagnostic picture — not the comparative size of either evidence base — is what determines which treatment is appropriate.

Cost, access, and booking an assessment

Practical access looks quite different for the two treatments. The ChondroFiller injection is priced from £3,000 per box, self-funded only — unavailable through the NHS and not covered by major private insurers including Bupa or AXA. Because the product is prescribed and imported individually for each patient, UK access is restricted to specialist centres with the supply infrastructure in place. The London Cartilage Clinic on Harley Street, led by Professor Paul Y.F. Lee, is the UK certified delivery centre.

PRP involves no specialist import chain: the procedure uses the patient's own blood, centrifuged on-site, and is available across a wide range of musculoskeletal clinics at considerably lower cost.

For patients whose imaging shows both a focal cartilage defect and synovial pathology, ChondroFiller injection can be combined in a single appointment with Arthrosamid — which addresses the synovial lining rather than the cartilage surface, serving a different anatomical role. More complex presentations may incorporate MSC delivery. Combined protocols range from approximately £6,000 to £11,000 depending on the components involved.

In all cases, treatment selection should follow diagnosis rather than precede it. A specialist consultation at which imaging is reviewed and the lesion properly characterised is the necessary first step. Assessments for Liquid Cartilage™ are available at the London Cartilage Clinic on Harley Street; bookings can be made via londoncartilage.com.